Blackstone to submit bid for stake in India's Cipla - report
Reuters
Published Aug 04, 2023 12:12AM ET
Updated Aug 04, 2023 12:50AM ET
(Reuters) - U.S.-based private equity fund Blackstone (NYSE:BX) will submit a bid next week to acquire a 33.47% stake in Indian drugmaker Cipla (NS:CIPL), the Economic Times reported on Friday, citing people in the know.
The stake sale will formally start the exit of the Hamied family who had founded Cipla in 1935, the report added.
Cipla and Blackstone did not immediately respond to Reuters' request for comment.
The move will also trigger an open offer for an additional 26% of Cipla, upon full subscription of which Blackstone would end up owning as much as 59.4% of Cipla's stake, according to the report.
Last Month, Moneycontrol had reported that top shareholders of the pharma major, which includes Blackstone are in talks to sell a part of their stake to private equity players.
Shares of the company have risen over 14% since the Moneycontrol report, and hit record high on Friday.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.